Related Experiment Videos
Body dysmorphic disorder
1Harrogate Clinic, Lasercare Clinics, North Yorkshire, England.
Dermatologic Clinics
|July 1, 1996
Summary
Selective serotonin reuptake inhibitors significantly improve outcomes for body dysmorphic disorder, a condition affecting up to 1% of the US population. These medications offer hope for managing this disabling disorder and reducing suicide risk.
Area of Science:
- Psychiatry
- Clinical Psychology
Background:
- Body dysmorphic disorder (BDD) is a challenging mental health condition characterized by obsessive preoccupation with perceived flaws in appearance.
- BDD affects up to 1% of the US population, often co-occurring with depression and obsessional features.
- The disorder carries a significant risk of suicide.
Purpose of the Study:
- To review the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating body dysmorphic disorder.
- To highlight the impact of SSRIs on managing perceived body ugliness and associated symptoms.
Main Methods:
- Literature review of studies investigating SSRI treatment for BDD.
- Analysis of patient response rates to SSRIs in clinical settings.
Main Results:
- A significant proportion of patients with BDD demonstrate positive responses to SSRIs.
- SSRIs have revolutionized the treatment landscape for this disabling disorder.
- Obsessive features and depression are common in BDD patients, with SSRIs showing efficacy in managing these aspects.
Conclusions:
- Selective serotonin reuptake inhibitors are a cornerstone in the management of body dysmorphic disorder.
- Effective treatment of BDD with SSRIs can lead to improved quality of life and reduced suicide risk.